Investors

investor people image

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Osiris Appoints Linda Palczuk to serve as its President & CEO
COLUMBIA, Md., June 26, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors has appointed Ms. Linda Palczuk, age 55, to serve as President and CEO, effective July 10, 2017. She will stand for election to the Board of Directors at the next shareholder meeting.  Ms. Palczuk had
View HTML
Toggle Summary Osiris Announces Electronically Available Case Study in a Peer-Reviewed Journal:  Open Surgical Implantation of a Viable Cryopreserved Placental Membrane after Decompression and Neurolysis of Common Peroneal Nerve
COLUMBIA, Md., June 14, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that a new peer reviewed manuscript entitled "Open Surgical Implantation of a Viable Cryopreserved
View HTML
Toggle Summary Osiris Appoints David White to its Board of Directors
COLUMBIA, Md., May 31, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on May 30th, 2017, appointed Mr. David White as a director, upon recommendation of the Nominating Committee.  The Board of Directors also appointed Mr. White as a member of the Audit
View HTML
Toggle Summary Osiris Announces Scientific Manuscript Comparing Impact of Preservation Methods on Tissue Integrity and Functionality is Available Electronically in Peer-Reviewed Journal
COLUMBIA, Md., April 13, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that that a new peer-reviewed manuscript entitled "Understanding the Impact of Preservation Methods
View HTML
Toggle Summary Osiris Therapeutics to Present 29 Advanced Clinical and Scientific Abstracts, Including a Late-Breaking Abstract on its New Ambient Viable Tissue Preservation Technology
COLUMBIA, Md., April 04, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, will present advanced clinical and scientific research at the Symposium on Advanced Wound Care (SAWC) and Wound
View HTML
Toggle Summary Osiris Therapeutics Announces Change in its Board of Directors
COLUMBIA, Md., March 31, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), announced today the passing of one of its Board Members, Yves Huwyler. "It deeply saddens me to announce the untimely loss of a dear friend and most valued Partner and Director Yves Huwyler, who died at the age of 44, after a long struggle with
View HTML
Toggle Summary Osiris Therapeutics Launches Prestige™ Lyotechnology, a Novel Method for Ambient Storage of Living Cells and Tissues
COLUMBIA, Md., March 30, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced today that it has developed cutting edge technology enabling the preservation of living cells and tissues
View HTML
Toggle Summary Osiris Therapeutics, Inc. Completes Restatement of 2014 Financial Statements
COLUMBIA, Md., March 27, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (Pink Sheets:OSIR), a leading regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, announced that it completed the restatement of its 2014 financial statements by filing an amended Annual Report on
View HTML
Toggle Summary Osiris Receives Notice of Delisting from NASDAQ
COLUMBIA, Md., March 10, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) (the "Company") announced today that the Company received a letter from the NASDAQ Stock Market ("NASDAQ") stating that trading of the Company's common stock will be suspended at the opening of business on Tuesday, March 14, 2017. The letter also states that
View HTML
Toggle Summary Osiris Appoints Uwe Sommer and Thomas Knapp to its Board of Directors
COLUMBIA, Md. , Feb. 10, 2017 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR) is pleased to announce that its Board of Directors, at a Board Meeting on February 7th, 2017, confirmed the appointment of Messrs. Uwe Sommer and Thomas J. Knapp as Directors, upon recommendation of the Nominating Committee, and each will stand for election
View HTML